A triple-drug cocktail containing the anti-malarial drug hydroxychloroquine significantly lowered the hospitalization and the death rate of COVID-19 patients, a peer-reviewed study suggests.
The study, led by Dr. Vladimir Zelenko in partnership with German doctors Martin Scholz and Roland Derwand, examined the effectiveness of the triple therapy containing zinc, low-dose hydroxychloroquine, and azithromycin on 141 COVID-19 patients aged between 40 and 67.